Myatorlip (Atorvastatin, Ezetimibe)

Myatorlip is indicated for lipid disorders and is used to modify cholesterol metabolism in several clinical settings.

• Hypercholesterolemia: lowers LDL‑cholesterol to reduce risk of atherosclerotic disease.
• Mixed dyslipidemia: decreases both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol.
• Primary hyperlipidemia: provides combined inhibition of hepatic synthesis and intestinal absorption of cholesterol.
• Prevention of cardiovascular events: used as adjunct therapy to lower incidence of myocardial infarction and stroke.
• Secondary prevention of cardiovascular disease: supports risk reduction in patients with established coronary artery disease when added to diet and lifestyle measures.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL particles. Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter on enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. The dual action results in additive reductions in plasma LDL‑cholesterol and total cholesterol in patients with elevated lipid levels.

Adverse reactions reported with Myatorlip reflect the known safety profile of its components.

Common Side Effects

• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Abdominal pain: discomfort in the stomach area.
• Diarrhea: loose stools.
• Nausea: feeling of sickness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury.
• Elevated liver enzymes: indicating possible hepatic injury.
• Severe allergic reaction: including rash, swelling, or anaphylaxis.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

When prescribing Myatorlip, clinicians should consider several precautionary measures to ensure patient safety.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women.
• Liver disease: assess hepatic function before initiation and monitor periodically.
• Renal impairment: dose adjustment may be required in severe renal dysfunction.
• Drug interactions: review concomitant medications that affect statin metabolism.
• Muscle disorders: discontinue if signs of myopathy or unexplained muscle pain develop.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Myatorlip may interact with other medicines; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure and risk of myopathy.
• Gemfibrozil: synergistic effect on muscle toxicity leading to rhabdomyolysis.
• Cyclosporine: raises statin plasma levels, heightening risk of liver and muscle injury.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Niacin: combined use can increase risk of hepatotoxicity.
• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption, diminishing efficacy.